
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5980384/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Uric acid and uric acid/creatinine ratio and their correlations with the hemorheological determinants in subjects with subclinical carotid atherosclerosis. Clinical Hemorheology and Microcirculation, 2022, , 1-9.	0.9	1
2	High Output Heart Failure in Multiple Myeloma: Pathogenetic Considerations. Cancers, 2022, 14, 610.	1.7	6
3	Association between Tpeak-Tend/QT and major adverse cardiovascular events in patients with Takotsubo syndrome. Acta Cardiologica, 2021, 76, 732-738.	0.3	7
4	Comparison between whole blood viscosity measured and calculated in subjects with monoclonal gammopathy of undetermined significance and in patients with multiple myeloma: Re-evaluation of our survey. Clinical Hemorheology and Microcirculation, 2021, 79, 475-483.	0.9	4
5	Reflections on the unexpected laboratory finding of hemorheological alterations observed in some haematological disorders. Microvascular Research, 2021, 136, 104171.	1.1	7
6	The function of matrix metalloproteinase-9 (MMP-9) and its tissue inhibitor (TIMP-1) in several clinical conditions: Results and analysis of our survey. Clinical Hemorheology and Microcirculation, 2021, 78, 401-416.	0.9	5
7	Behaviour of carbonyl groups in several clinical conditions: Analysis of our survey. Clinical Hemorheology and Microcirculation, 2020, 74, 299-313.	0.9	6
8	Plasma viscosity pattern and erythrocyte aggregation in two patients with congenital afibrinogenemia. Blood Coagulation and Fibrinolysis, 2020, 31, 330-332.	0.5	1
9	COVID-19 Sepsis and Microcirculation Dysfunction. Frontiers in Physiology, 2020, 11, 747.	1.3	79
10	Red blood cell deformability in multiple myeloma1. Clinical Hemorheology and Microcirculation, 2018, 69, 233-238.	0.9	8
11	Analysis of the Blood Viscosity Behavior in the Sicilian Study on Juvenile Myocardial Infarction. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 1276-1281.	0.7	9
12	Chloride/sodium ratio and sodium-chloride difference in patients with renal failure and metabolic acidosis in hemodialysis treatment. Trace Elements and Electrolytes, 2018, 35, 51-60.	0.1	0
13	Clinical disorders responsible for plasma hyperviscosity and skin complications. European Journal of Internal Medicine, 2017, 42, 24-28.	1.0	5
14	Matrix Metalloproteases in Arterial Hypertension and their Trend after Antihypertensive Treatment. Kidney and Blood Pressure Research, 2017, 42, 347-357.	0.9	25
15	Gelatinases and physical exercise. Medicine (United States), 2017, 96, e8072.	0.4	33
16	Clinical conditions responsible for hyperviscosity and skin ulcers complications. Clinical Hemorheology and Microcirculation, 2017, 67, 25-34.	0.9	8
17	Gelatinases and their tissue inhibitors in a group of subjects with obstructive sleep apnea syndrome. Clinical Hemorheology and Microcirculation, 2016, 62, 27-34.	0.9	17
18	Lipid peroxidation and nitric oxide metabolites in a group of subjects with obstructive sleep apnea syndrome. Clinical Hemorheology and Microcirculation, 2016, 63, 163-168.	0.9	1

#	Article	IF	CITATIONS
19	Fluidity and cytosolic Ca2+ concentration of circulating polymorphonuclear leukocytes at baseline in some chronic and acute clinical conditions: review of our survey. Trace Elements and Electrolytes, 2016, 33, 17-21.	0.1	0
20	Interrelationships between oxidative stress and MMP-9 in subjects with severe obstructive sleep apnea syndrome. , 2016, , .		0
21	Behaviour of the plasma concentration of gelatinases and their tissue inhibitors in subjects with venous leg ulcers. Clinical Hemorheology and Microcirculation, 2015, 60, 309-316.	0.9	9
22	Protein carbonyl groups in trained subjects before and after a cardiopulmonary test. Clinical Hemorheology and Microcirculation, 2015, 59, 27-35.	0.9	1
23	Nitric oxide metabolites and erythrocyte deformability in a group of subjects with obstructive sleep apnea syndrome. Clinical Hemorheology and Microcirculation, 2015, 59, 45-52.	0.9	10
24	Lipid Peroxidation, Nitric Oxide Metabolites, and Their Ratio in a Group of Subjects with Metabolic Syndrome. Oxidative Medicine and Cellular Longevity, 2014, 2014, 1-8.	1.9	15
25	Study of the Correlations among Some Parameters of the Oxidative Status, Gelatinases, and Their Inhibitors in a Group of Subjects with Metabolic Syndrome. Mediators of Inflammation, 2014, 2014, 1-7.	1.4	9
26	Nitric oxide metabolites (nitrite and nitrate) in several clinical condition. Clinical Hemorheology and Microcirculation, 2014, 56, 359-369.	0.9	26
27	Hemorheological abnormalities in human arterial hypertension. Korea Australia Rheology Journal, 2014, 26, 199-204.	0.7	8
28	Behavior of the total antioxidant status in a group of subjects with metabolic syndrome. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2014, 8, 166-169.	1.8	5
29	Oxidative status in nondiabetic middle-aged subjects with metabolic syndrome: Preliminary data. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, e17-e18.	1.1	2
30	Protein oxidation in a group of subjects with metabolic syndrome. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2013, 7, 38-41.	1.8	12
31	Protein oxidation in chronic kidney disease. Clinical Hemorheology and Microcirculation, 2013, 54, 409-413.	0.9	14
32	Lipid peroxidation and nitric oxide metabolites in sedentary subjects and sportsmen before and after a cardiopulmonary test. Clinical Hemorheology and Microcirculation, 2013, 54, 39-49.	0.9	1
33	Gelatinases and Their Tissue Inhibitors in a Group of Subjects With Metabolic Syndrome. Journal of Investigative Medicine, 2013, 61, 978-983.	0.7	43
34	Behaviour of protein carbonyl groups in juvenile myocardial infarction. Clinical Hemorheology and Microcirculation, 2013, 53, 297-302.	0.9	8
35	Protein carbonyl groups in trained subjects. Clinical Hemorheology and Microcirculation, 2012, 51, 111-116.	0.9	4
36	Evaluation of nitric oxide metabolites in a group of subjects with metabolic syndrome. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2012, 6, 132-135.	1.8	21

#	Article	IF	CITATIONS
37	Erythrocyte deformability evaluated by laser diffractometry in polycythemia vera. Clinical Hemorheology and Microcirculation, 2012, 50, 189-192.	0.9	7
38	Myeloperoxidase in chronic kidney disease. Trace Elements and Electrolytes, 2012, 29, 83-84.	0.1	0
39	Interrelationships between lipid peroxidation and total antioxidant status in sedentary controls and unprofessional athletes. Clinical Hemorheology and Microcirculation, 2010, 45, 35-38.	0.9	0
40	Behaviour of nitric oxide metabolites in unprofessional athletes before and after a cardiopulmonary test. Clinical Hemorheology and Microcirculation, 2010, 44, 283-286.	0.9	3
41	Role of genetic polymorphisms in myocardial infarction at young age. Clinical Hemorheology and Microcirculation, 2010, 46, 291-298.	0.9	25
42	Pathophysiology of polymorphonuclear leukocyte in arterial hypertension. Clinical Hemorheology and Microcirculation, 2009, 41, 209-218.	0.9	15
43	Influence of risk factors on nitric oxide metabolites at the initial stage of juvenile acute myocardial infarction. Clinical Hemorheology and Microcirculation, 2009, 41, 35-37.	0.9	1
44	Nitric Oxide Metabolites, Leukocyte Activation Markers and Oxidative Status in Dialyzed Subjects. Blood Purification, 2009, 27, 194-198.	0.9	15
45	Lipid peroxidation and total antioxidant status in unprofessional athletes before and after a cardiopulmonary test. Clinical Hemorheology and Microcirculation, 2009, 43, 233-239.	0.9	15
46	Elastase, myeloperoxidase, nitric oxide metabolites and oxidative status in subjects with clinical stable chronic renal failure on conservative treatment. Clinical Hemorheology and Microcirculation, 2009, 43, 251-256.	0.9	12
47	Erythrocyte Deformability and Nitric Oxide Metabolites in Athletes Before and After a Cardiopulmonary Test. Clinical Journal of Sport Medicine, 2009, 19, 306-310.	0.9	4
48	Relationship between elastase and total antioxidant status in young subjects with recent myocardial infarction. Clinical Hemorheology and Microcirculation, 2008, 40, 31-36.	0.9	1
49	Nitric oxide metabolites (nitrite and nitrate) in young patients with recent acute myocardial infarction. Clinical Hemorheology and Microcirculation, 2008, 40, 157-163.	0.9	5
50	Wine, Diet, and Arterial Hypertension. Angiology, 2007, 58, 92-96.	0.8	27
51	Persistence of High Plasma Elastase Level in Young Subjects With Acute Myocardial Infarction. Clinical and Applied Thrombosis/Hemostasis, 2007, 13, 224-225.	0.7	1
52	Wine consumption and renal diseases: new perspectives. Nutrition, 2007, 23, 598-602.	1.1	40
53	Polymorphonuclear Leukocyte Integrinsin Deep Venous Thrombosis. Clinical and Applied Thrombosis/Hemostasis, 2005, 11, 95-97.	0.7	7
54	Plasma markers of platelet and polymorphonuclear leukocyte activation in young adults with acute myocardial infarction. Clinical Hemorheology and Microcirculation, 2005, 32, 67-74.	0.9	12

#	Article	IF	CITATIONS
55	Techniques to evaluate erythrocyte deformability in diabetes mellitus. Acta Diabetologica, 2004, 41, 99-103.	1.2	30
56	Haematocrit in metabolic syndrome. Diabetic Medicine, 2004, 21, 299-299.	1.2	2
57	Polymorphonuclear leukocyte integrin pattern, at baseline and after activation, in type 2 diabetic subjects with macrovascular complications. Acta Diabetologica, 2003, 40, 14-19.	1.2	11
58	Diabetes mellitus: oxidative stress and wine. Current Medical Research and Opinion, 2003, 19, 581-586.	0.9	42
59	Polymorphonuclear leukocyte membrane fluidity, at baseline and after in vitro activation, in obesity with or without diabetes mellitus. Acta Diabetologica, 2002, 39, 29-33.	1.2	17
60	Granulocyte integrins before and after activation in acute ischaemic stroke. Journal of the Neurological Sciences, 2001, 186, 23-26.	0.3	24
61	Polymorphonuclear leucocyte rheology and cytosolic Ca2+ content after activation in chronic renal failure. Nephrology, 2001, 6, 113-117.	0.7	1
62	Polymorphonuclear leukocyte integrin pattern in acute ischemic stroke. Acta Neurologica Scandinavica, 2001, 103, 136-137.	1.0	1
63	Plasma viscosity and insulin resistance in metabolic syndrome. International Journal of Obesity, 2001, 25, 1856-1857.	1.6	15
64	Polymorphonuclear Integrins, Membrane Fluidity, and Cytosolic Ca ²⁺ Content After Activation in Essential Hypertension. Hypertension, 2000, 36, 813-817.	1.3	11
65	Chronic renal failure: behaviour of the polymorphonuclear leukocyte membrane fluidity at baseline and after chemotactic activation. Nephrology Dialysis Transplantation, 1999, 14, 253-254.	0.4	Ο
66	Polymorphonuclear leukocyte membrane fluidity and cytosolic Ca 2+ concentration in diabetes mellitus. Acta Diabetologica, 1998, 35, 158-160.	1.2	5
67	Hemorheologic profile of hyperlipidemic patients treated with gemfibrozil. Current Therapeutic Research, 1996, 57, 327-335.	0.5	0
68	Leukocyte Flow Properties, Polymorphonuclear Membrane Fluidity, and Cytosolic Ca 2+ Content in Subjects with Vascular Atherosclerotic Disease with and Without Noninsulin-Dependent Diabetes Mellitus. Angiology, 1996, 47, 757-763.	0.8	1
69	Platelet membrane fluidity and platelet membrane lipid pattern in essential hypertension. American Journal of Hypertension, 1995, 8, 82-86.	1.0	9
70	Red Cell Membrane Protein Lateral Mobility in Vascular Atherosclerotic Disease: Preliminary Report. Microvascular Research, 1993, 45, 314-317.	1.1	4
71	Diabetes Mellitus: Mean Erythrocyte Aggregation, Glycometabolic Pattern, Red Cell Ca2+ Content, and Erythrocyte Membrane Dynamic Properties. Microvascular Research, 1993, 46, 401-405.	1.1	17
72	Effect of nimodipine on rheologic parameters in patients with chronic cerebrovascular disease. Current Therapeutic Research, 1992, 52, 899-905.	0.5	1

#	Article	IF	CITATIONS
73	Effect of mesoglycan on macrorheologic and microrheologic parameters. Current Therapeutic Research, 1992, 52, 412-418.	0.5	4